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All the contrast agents used worldwide for magnetic resonance imaging (MRI) are now gadolinium-based; with a few exceptions, the iron and manganese agents are no longer available. In gadolinium-based contrast agents, the gadolinium atom is attached to a chelate to protect the body from exposure to the toxic gadolinium atom. It is very important that the gadolinium atom is tightly bound to the chelate, so that exchange of the gadolinium with metals in the body (transmetallation) does not occur. The chelates used are either linear or macrocyclic, and in the macrocyclic agents the gadolinium is more tightly bound.
Since early 2006, the trend has been towards use of the macrocyclic agents (Gadobutrol, Gadoterate meglumine, Gadoteridol) rather than linear agents, and the macrocyclic agents are now the market leaders in Europe. The biggest change has been in Denmark, where the so-called nephrogenic systemic fibrosis (NSF) high-risk agents (Gadodiamide, Gadoversetamide, Gadopentetate dimeglumine) are now no longer authorized for administration. The clear trend towards almost sole use of macrocyclic agents, with the possible exception of specific liver imaging, has introduced a new situation. If this development continues, we will be left with only a few agents.
The patents on most, if not all, of the current contrast agents for MRI have expired and generic agents have been introduced. Over recent years, several generic copies of gadoterate meglumine (Dotarem Õ , Guerbet, Roissy CDG, France) have been registered by the authorities (Table 1) . Surprisingly, generic versions of the other macrocyclic agents have not yet been introduced.
The drug developer had the expense of developing the contrast agent and getting it approved, and then had 20 years to recover their costs. The marketing authorization holders (MAH) who sell generic agents have borne none of the development costs, and in most countries the introduction of a generic agent has meant a reduction in price. In addition, all the vendors are keen to offer competitive prices to increase their market share, so the users and the hospital administrators are happy.
The developer usually has research laboratories and a medical department, but these are rare in generic companies. Developers often have an ongoing program of in vitro and in vivo research and publish the results in peer-reviewed journals, but generic companies do not do research and I was unable to find a publication in a peer-reviewed journal written by generic company employees. Continued studies after the contrast agent has been introduced, e.g. phase 4 studies, are important and are only conducted by the developer.
The package-insert and the summary of product characteristics (SPC) are mandatory parts of marketing a drug and these are approved by the health authorities. The original package-inserts and SPCs are usually prepared by the developer and then just copied by the generic company.
Associated with their scientific activities, the developer has contrast agent specialists. Contrast agents differ from other drugs such as antibiotics or antihypertensive drugs because they do not have any therapeutic effect and specialists who know a great deal about therapeutic drugs may not have a similar understanding of contrast agents. Contrast agent specialists are an important resource and generic companies often refer queries to the contrast agent developer to take advantage of their expertise. Such specialists become particularly important if an unknown adverse reaction occurs. They are able to investigate the problem immediately and provide the regulatory authorities with appropriate information. If there is another serious adverse effect of gadolinium-based agents such as NSF, who will take care of the clinical and experimental investigations? Many of the in vitro and in vivo experimental and clinical studies conducted by the developers were extremely helpful in our understanding of the pathogenesis of NSF (1-9), but nonetheless it took nine years for the link between gadoliniumbased agents and NSF to be recognized. Once the link between NSF and the linear chelates in patients with impaired renal function had been identified, and linear agents were no longer used in such patients, the numbers of new NSF cases reported rapidly dropped to zero. If contrast agent specialists are no longer employed by the drug developers, where will they come from in the future?
There are some basic expenses for the company which holds the authorization for a drug. Until now, the contrast agent developers have borne these costs, but will that be possible with increasing price competition in the market and increasing numbers of generic versions of each contrast agent? It would seem fairer that the expense of the drug authorization should be paid by all MAHs per vial sold.
Gadolinium-based contrast agents are a good example of the fact that adverse reactions may not be observed during the first 20 years, when generic contrast agents are not available. It took 17 years before the link between gadolinium and NSF was found. Gadolinium accumulation in the brain was found after 25 years of use. Have we seen all adverse reactions yet? One must remember that in the beginning only very few patients were examined with enhanced MRscanning as there were only very few scanners available. The patients were highly selected. Nowadays several million injections are given every year. 1989, when the first gadolinium-based agent was introduced, cannot be compared to 2017.
The current gadolinium-based contrast agents are not ideal but they are very close to being inert, and the incidence of moderate and severe acute adverse reactions is below 1 per 1000. Developing new agents is very expensive and, because of the low incidence of adverse effects, demonstrating a significant reduction in side effects will require thousands of patients in the phase 3 trials. There is therefore a low likelihood of recouping the investment, making a search for new gadolinium-based agents unlikely in the new era of generic agents.
And finally, a frequent question from colleagues: is the generic product really identical to the original in all aspects? The answer depends on who you ask. The developer may say no because the synthetic process is different and the generic company may say yes because the final chemical compound is the same.
In the current era of generic agents there needs to be a debate about the future of gadolinium-based contrast agents. 
